drugset / Trial / NCT01573533
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
Phase 2
Completed
9 enrolled
Mayo Clinic
Genentech, Inc. · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Institutes of Health (NIH) · collabRush University Medical Center · collabUniversity Health Network, Toronto · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional therapies.
Timeline
- Start
- 2013-10
- Primary completion
- 2018-11-15
- Completion
- 2018-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |